PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 10, 2025Frontiers in Oncology0 citationsOpen Access

Case Report: A long-term survival case of primary malignant melanoma of the lung with meningeal metastasis

View Full Paper
YWYing WuYWYanchun WeiXMXiang Meng

Key Points

  • Overall survival of the patient was 30 months despite the poor prognosis associated with lung malignant melanoma.
  • Radiation therapy combined with immunotherapy was the main treatment approach, potentially improving survival outcomes.
  • Primary malignant melanoma of the lung often has a difficult diagnosis and can be misdiagnosed as other conditions.
  • The case showcases the need for additional research into effective treatment strategies for this rare type of melanoma.

Abstract

Background Malignant melanoma originating in the lungs is relatively rare, accounting for only 0.01% of lung tumors, and has a poor prognosis and is prone to distant metastasis. Notably, melanoma is the third most common source of intracranial metastases in adults, after lung and breast cancer. Primary malignant melanoma of the lung with meningeal metastasis is more rare and has a worse prognosis. There is no effective and unified treatment plan in clinical practice, and the main treatment is comprehensive treatment, which mainly includes surgery, radiation therapy, immunotherapy and targeted therapy. Case presentation The patient was a 52-year-old male with no history of smoking. PET-CT showed a mass in the main bronchus of the right lung, consistent with the metabolic changes of malignant melanoma. Combined with pathology, we finally identified the patient as a primary pulmonary malignant melanoma. About two years later, the patient developed meningeal metastases. The patients was mainly treated with radiation therapy combined with immunotherapy, and the overall survival was about 30 months. Conclusions The diagnosis of pulmonary primary malignant melanoma requires a combination of many factors and is easy to be misdiagnosed. At present, there is no specific effective treatment plan, and such patients have a poor prognosis, are prone to distant metastasis, and their survival will be greatly shortened. The survival period of the patient in this case is longer than the average survival period of such patients, and the possibility of benefiting from immunotherapy is higher. Radiotherapy also reduces the discomfort symptoms of the patient to a certain extent, prolongs the survival of the patient, and provides certain ideas for clinical treatment.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Wu et al. (2025) studied this question.

synapsesocial.com/papers/68c1c64554b1d3bfb60f26e0https://doi.org/10.3389/fonc.2025.1491350
Ask AI
Helpful
Bookmark
Share
View Full Paper